SSSW(SH:688399) Zhong Guo Jing Ying Bao·2025-08-27 23:58Core Viewpoint - The company, Shuoshi Biotechnology, announced voluntary salary reductions for several board members and senior management to support operational cost optimization and enhance management efficiency in response to challenging global economic conditions [1][3]. Salary Reduction Details - The honorary chairman, Fang Yongsheng, and the chairman and general manager, Wang Guoqiang, will have their annual salaries reduced by 50% starting from August 15, 2025 [2][3]. - Other executives, including Liu Zhonghua and Hu Yuanyuan, will see a 40% reduction, while the financial director, Meng Yuanyuan, and employee supervisors will have reductions of 10% and 5%, respectively [2][3]. Company Performance - Shuoshi Biotechnology reported a significant decline in net profit, with a loss of 374 million yuan in 2023, a 120.45% decrease year-on-year [5][6]. - The company’s revenue for the first half of 2025 was 176 million yuan, a decrease of 1.05% compared to the previous year, with a net profit of 3.99 million yuan, down 86.35% year-on-year [5][6]. Future Strategies - In addition to salary adjustments, the company plans to continue cost-cutting measures and enhance market expansion efforts to improve operational efficiency and competitiveness [4][5].